RATIONALE: The kappa opioid receptor (KOR) antagonist, JDTic, was reported to prevent stress-induced reinstatement of cocaine-maintained responding and to have antidepressant-like effects. OBJECTIVES: Our objectives were to determine whether analogs of JDTic retained KOR antagonist activity and whether an orally effective analog prevented footshock-induced cocaine reinstatement. METHODS: RTI-194 (i.g. 1-30 mg/kg, s.c. 0.3-10 mg/kg, and i.p. 30 mg/kg), RTI-212 (s.c. 0.3-10 mg/kg and i.p. 30 mg/kg), and RTI-230 (i.g. 3-30 mg/kg and i.p. 1-30 mg/kg) were evaluated for their ability to block diuresis induced by 10-mg/kg U50,488 in rats. RTI-194 was additionally evaluated i.g. (3-100 mg/kg) for its ability to prevent footshock-induced reinstatement of responding previously reinforced with 0.5-mg/kg/inf cocaine. RESULTS: RTI-194 significantly (p < 0.05) attenuated U50,488-induced diuresis when given i.g., s.c., and i.p. RTI-194s effectiveness increased 1 week following administration. RTI-212 was ineffective. RTI-230 was ineffective when given i.g., but blocked diuresis at 24 h and 8 days (1, 10, and 30 mg/kg), 15 days (10 and 30 mg/kg), 22 and 29 days (30 mg/kg) following i.p. administration. Footshock reinstated responding in vehicle-but not RTI-194 (30 and 100 mg/kg)-treated rats. CONCLUSIONS: RTI-194 and RTI-230 are effective KOR antagonists, and RTI-194 is now included with JDTic as the only reported compounds capable of antagonizing the KOR following oral administration. The failure of stress to reinstate cocaine seeking in rats treated with RTI-194 is consistent with results reported with JDTic, although it had less efficacy in lowering response levels than JDTic, suggesting a diminished overall effectiveness relative to it.
RATIONALE: The kappa opioid receptor (KOR) antagonist, JDTic, was reported to prevent stress-induced reinstatement of cocaine-maintained responding and to have antidepressant-like effects. OBJECTIVES: Our objectives were to determine whether analogs of JDTic retained KOR antagonist activity and whether an orally effective analog prevented footshock-induced cocaine reinstatement. METHODS:RTI-194 (i.g. 1-30 mg/kg, s.c. 0.3-10 mg/kg, and i.p. 30 mg/kg), RTI-212 (s.c. 0.3-10 mg/kg and i.p. 30 mg/kg), and RTI-230 (i.g. 3-30 mg/kg and i.p. 1-30 mg/kg) were evaluated for their ability to block diuresis induced by 10-mg/kg U50,488 in rats. RTI-194 was additionally evaluated i.g. (3-100 mg/kg) for its ability to prevent footshock-induced reinstatement of responding previously reinforced with 0.5-mg/kg/inf cocaine. RESULTS:RTI-194 significantly (p < 0.05) attenuated U50,488-induced diuresis when given i.g., s.c., and i.p. RTI-194s effectiveness increased 1 week following administration. RTI-212 was ineffective. RTI-230 was ineffective when given i.g., but blocked diuresis at 24 h and 8 days (1, 10, and 30 mg/kg), 15 days (10 and 30 mg/kg), 22 and 29 days (30 mg/kg) following i.p. administration. Footshock reinstated responding in vehicle-but not RTI-194 (30 and 100 mg/kg)-treated rats. CONCLUSIONS:RTI-194 and RTI-230 are effective KOR antagonists, and RTI-194 is now included with JDTic as the only reported compounds capable of antagonizing the KOR following oral administration. The failure of stress to reinstate cocaine seeking in rats treated with RTI-194 is consistent with results reported with JDTic, although it had less efficacy in lowering response levels than JDTic, suggesting a diminished overall effectiveness relative to it.
Authors: Jay P McLaughlin; Shuang Li; Joseph Valdez; Theodore A Chavkin; Charles Chavkin Journal: Neuropsychopharmacology Date: 2006-06 Impact factor: 7.853
Authors: Benjamin B Land; Michael R Bruchas; Selena Schattauer; William J Giardino; Megumi Aita; Daniel Messinger; Thomas S Hnasko; Richard D Palmiter; Charles Chavkin Journal: Proc Natl Acad Sci U S A Date: 2009-10-28 Impact factor: 11.205
Authors: Ivy Carroll; James B Thomas; Linda A Dykstra; Arthur L Granger; Richard M Allen; James L Howard; Gerald T Pollard; Mario D Aceto; Louis S Harris Journal: Eur J Pharmacol Date: 2004-10-06 Impact factor: 4.432
Authors: Glenn R Valdez; Donna M Platt; James K Rowlett; Daniela Rüedi-Bettschen; Roger D Spealman Journal: J Pharmacol Exp Ther Date: 2007-08-16 Impact factor: 4.030
Authors: Benjamin B Land; Michael R Bruchas; Julia C Lemos; Mei Xu; Erica J Melief; Charles Chavkin Journal: J Neurosci Date: 2008-01-09 Impact factor: 6.167
Authors: Erica J Melief; Mayumi Miyatake; F Ivy Carroll; Cécile Béguin; William A Carlezon; Bruce M Cohen; Sarah Grimwood; Charles H Mitch; Linda Rorick-Kehn; Charles Chavkin Journal: Mol Pharmacol Date: 2011-08-10 Impact factor: 4.436
Authors: Gerald A Deehan; David L McKinzie; F Ivy Carroll; William J McBride; Zachary A Rodd Journal: Pharmacol Biochem Behav Date: 2012-03-10 Impact factor: 3.533
Authors: Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin Journal: J Nat Prod Date: 2013-01-17 Impact factor: 4.050
Authors: Shainnel O Eans; Michelle L Ganno; Kate J Reilley; Kshitij A Patkar; Sanjeewa N Senadheera; Jane V Aldrich; Jay P McLaughlin Journal: Br J Pharmacol Date: 2013-05 Impact factor: 8.739
Authors: Nicholas M Graziane; Abigail M Polter; Lisa A Briand; R Christopher Pierce; Julie A Kauer Journal: Neuron Date: 2013-03-06 Impact factor: 17.173